RxSight, Inc.
RxSight, Inc. (Nasdaq: RXST) is a medical technology company focused on customized vision after cataract surgery. Its RxSight system combines Light Adjustable Lenses (LAL and LAL+) made from photosensitive silicone, an office-based Light Delivery Device (LDD) and related accessories. After a surgeon implants the lens,… From the company’s description.
Over the twelve months to Sep 30, 2026, RxSight, Inc. reported revenue of $121.83M, down 14.3% from a year earlier, and a net loss of $53.36M. Its operating margin was −50.4%, and operations generated $23.67M in cash. In fiscal 2025, it reported revenue of $134.48M, down 3.9% from fiscal 2024, and a net loss of $38.94M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RxSight, Inc. does
In the company’s own words
RxSight, Inc. (Nasdaq: RXST) is a medical technology company focused on customized vision after cataract surgery. Its RxSight system combines Light Adjustable Lenses (LAL and LAL+) made from photosensitive silicone, an office-based Light Delivery Device (LDD) and related accessories. After a surgeon implants the lens, the doctor uses the LDD to adjust its refractive power with ultraviolet light, tailoring vision to the patient’s needs and preferences. The company sells to ophthalmology practices and supports surgeons and their staff through training, clinical specialists and ongoing practice services; patients receive the lens and follow-up light treatments through those practices. RxSight uses a “razor and razor blade” model, selling LDDs to establish an installed base and generating ongoing sales of lenses. Its commercial efforts began in the United States in 2019. As of December 31, 2025, it had 1,134 LDDs installed in ophthalmology practices, and surgeons had implanted approximately 300,000 of its lenses since inception. Its products have regulatory approval in the United States, Europe, Canada, Mexico, Singapore, Australia and South Korea.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- ALISO VIEJO, CA
- Fiscal year end
- December
- CIK
- 1111485
- SIC
- 3851
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RxSight, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RxSight, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RxSight, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RxSight, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RxSight, Inc.'s last four quarterly filings that the numbers alone won't show?”